Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

2019; Nature Portfolio; Volume: 5; Issue: 1 Linguagem: Inglês

10.1038/s41523-019-0111-0

2374-4677

Bruno V. Sinn, Chunxiao Fu, Rosanna Lau, Jennifer K. Litton, Tsung‐Heng Tsai, Rashmi K. Murthy, Alda L. Tam, Eleni Andreopoulou, Yun Gong, Ravi Murthy, Rebekah Gould, Ya Zhang, Tari A. King, Agnès Viale, Victor P. Andrade, Dilip D. Giri, Roberto Salgado, Ioanna Laı̈os, Christos Sotiriou, Esmeralda Celia Marginean, Danielle Kwiatkowski, Rachel M. Layman, Daniel J. Booser, Christos Hatzis, Vicente Valero, W. Fraser Symmans,

Gene expression and cancer classification

Abstract There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure both transcriptional activity and functional mutation. We developed the SET ER/PR index to measure gene expression microarray probe sets that were correlated with hormone receptors ( ESR1 and PGR ) and robust to preanalytical and analytical influences. We tested SET ER/PR index in biopsies of metastastic HR+/HER2− breast cancer against the treatment outcomes in 140 patients. Then we customized the SET ER/PR assay to measure 18 informative, 10 reference transcripts, and sequence the ligand-binding domain (LBD) of ESR1 using droplet-based targeted RNAseq, and tested that in residual RNA from 53 patients. Higher SET ER/PR index in metastatic samples predicted longer PFS and OS when patients received endocrine therapy as next treatment, even after adjustment for clinical-pathologic risk factors (PFS: HR 0.534, 95% CI 0.299 to 0.955, p = 0.035; OS: HR 0.315, 95% CI 0.157 to 0.631, p = 0.001). Mutated ESR1 LBD was detected in 8/53 (15%) of metastases, involving 1−98% of ESR1 transcripts (all had high SET ER/PR index). A signature based on probe sets with good preanalytical and analytical performance facilitated our customization of an accurate targeted RNAseq assay to measure both phenotype and genotype of ER-related transcription. Elevated SET ER/PR was associated with prolonged sensitivity to endocrine therapy in patients with metastatic HR+/HER2− breast cancer, especially in the absence of mutated ESR1 transcript.